Влияние черепно-мозговой травмы на фоне хронической алкогольной интоксикации в эксперименте на активность NA+/K+-АТФазы эритроцитов и возможность ее коррекции

Abstract

Комбинированная патология — черепно-мозговая травма на фоне алкогольной интоксикации у крыс приводила к наиболее выраженной дискоординации активности Mg2+- и Na+/K+-АТФазы. Применение нового биологически активного соединения — ниацин-оксиэтилидендифосфонатогерманата (МИГУ-4) в качестве фармакологического средства показало, что уже на 7-е сутки активность суммарной АТФазы нормализовалась, а активность Mg2+-зависимой Na+/K+-активируемой АТФазы достоверно выравнивалась и до 14-х суток лечения достигла контрольных величин. Было установлено, что МИГУ-4 обладает выраженной мембранотропной активностью, которая проявляется в нормализации активности АТФаз при тяжелой комбинированной экспериментальной патологии.Objective. The activity of Na+/K+-ATPase reflects the compensatory and adaptive reactions of red blood cells and indirectly affects the severity of their damage in combined pathology, which is traumatic brain injury on the background of alcohol intoxication. Materials and methods. The research was conducted under conditions of a chronic experiment on 84 male rats of the Wistar line weighing 170–250 g after 6 months after birth. Chronic alcoholic intoxication, which was accompanied by the formation of alcohol dependence, caused a 20-day experiment in the “benefits of ethanol” test. The animals were placed in individual boxes in which they had access to two drinkers: with pure water and 15% ethanol. Craniocerebral trauma was reproduced by drawing one strike on the crown — the occipital region of the brain with a falling weight weighing 100 g from a height of 80 cm, which is called a hit model. Results. Combined pathology — traumatic brain injury on the background of alcohol intoxication in rats led to the most pronounced discoordination of Mg2+-dependent Na+/K+-activated ATPase activity. The use of a new biologically active compound — niacin-hydroxyethylidene diphosphanate germanate (MIGU-4) as a pharmacological agent showed that already on the 7th day the activity of total ATPase was normalized, and the activity of Mg2+- and Na+/K+-ATPase were reliably aligned and up to 14 days of treatment reached control quantities. Conclusions. It was found that MIGU-4 has a pronounced membranotropic activity, which is expressed in the normalization of ATPase activity in severe combined experimental pathology